Viz.ai, developers of a synchronized healthcare software using artificial intelligence (AI), has raised $50 million in Series B funding. The investment was led by Greenoaks with participation from Threshold Ventures, CRV along with existing investors GV and Kleiner Perkins.
In February 2018, the U.S. Food and Drug Administration (FDA) granted a De Novo clearance for Viz LVO, a computer-aided triage and notification software.
Viz.ai is located in San Francisco and Tel Aviv.
[Image courtesy: Viz.ai]